Floatz logo

TANZISERTIB

Pulmonary Fibrosis

CelgeneSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
N-Acetyl-L-Cysteine
Boehringer Ingelheim
Phase 3BB
Nintedanib
Boehringer Ingelheim
Phase 3BB
Pirfenidone
Boehringer Ingelheim
Phase 2BB
Admilparant
Bristol-Myers Squibb
Phase 3BB
Sildenafil
Alicia Gerke
Phase 3BB

View all 38 →

Same molecule, other indications

TANZISERTIB is also rated in:

interstitial lung diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →